Q2 Earnings Estimate for BioLineRx Issued By Zacks Research

BioLineRx Ltd. (NASDAQ:BLRX) – Zacks Research issued their Q2 2026 earnings per share estimates for BioLineRx in a research report issued to clients and investors on Thursday, May 28th. Zacks Research analyst J. Vandermosten anticipates that the biotechnology company will post earnings of $0.00 per share for the quarter. Zacks Research also issued estimates for BioLineRx’s Q3 2026 earnings at $0.00 EPS, Q4 2026 earnings at $0.00 EPS, FY2026 earnings at $0.00 EPS and FY2028 earnings at $0.00 EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioLineRx in a research note on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.

BioLineRx Stock Performance

Shares of BLRX stock opened at $3.39 on Wednesday. BioLineRx has a 52 week low of $2.15 and a 52 week high of $6.59. The firm’s 50-day simple moving average is $2.67 and its two-hundred day simple moving average is $2.88. The firm has a market cap of $14.81 million, a price-to-earnings ratio of -1.77 and a beta of 1.53. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.43 and a current ratio of 1.58.

BioLineRx (NASDAQ:BLRX) last released its earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.68. The company had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $0.34 million. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.

BioLineRx Company Profile

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.